CFH rs3916970: What Your Genotype Means
The rs3916970 variant is a non-coding single-nucleotide polymorphism located within the complement factor H (CFH) gene locus on chromosome 1. Research suggests it acts as a tagging marker within common haplotypes that influence complement system activity and differential susceptibility to age-related macular degeneration (AMD). Because the direct evidence for this specific variant is limited, it is best understood as part of a larger cluster of CFH-related variations rather than an isolated risk factor.
What each genotype means
Typical risk baseline
You carry two copies of the major G allele for this non-coding CFH-region variant. Research evaluating this polymorphism and its correlated haplotypes suggests this genotype confers standard, baseline susceptibility to age-related macular degeneration (AMD). Because overall evidence for this specific tag variant is limited compared to major missense CFH markers, it does not represent an absolute prediction of eye health.
Carried by roughly 45% to 50% of individuals in European-ancestry populations.
Modestly altered AMD risk
You carry one copy of the A minor allele and one copy of the G allele at rs3916970. In genetic studies, this allele tags a CFH haplotype that has been examined for modest shifts in complement regulation and age-related macular degeneration (AMD) risk. However, published evidence directly tying this specific variant to disease remains limited and varies according to ancestral background.
Carried by approximately 40% to 45% of individuals of European ancestry.
Altered CFH haplotype status
You carry two copies of the minor A allele at rs3916970. In population studies, this genotype tags an alternative complement factor H (CFH) regulatory haplotype associated with altered statistical odds for age-related macular degeneration. Direct clinical evidence for this specific non-coding variant remains limited, and it should be interpreted alongside comprehensive lifestyle factors and stronger causal complement markers.
Found in approximately 8% to 10% of European populations.
Genomic Location and Variant Characteristics
The single-nucleotide polymorphism rs3916970 resides within the CFH locus positioned on chromosome 1q31.3. This variant consists of a single-base substitution (commonly involving C and T alleles) in a non-coding sequence of the gene. Non-coding variants do not alter the amino acid sequence of the resulting protein directly; instead, they often serve as regulatory markers or as genetic tags that travel alongside other functional mutations through linkage disequilibrium. Across the broader CFH genomic landscape, multiple non-coding markers help scientists trace specific ancestral haplotypes that shape immune protein expression.
The Biological Role of Complement Factor H
The CFH gene encodes complement factor H, an essential circulating glycoprotein that functions as a primary negative regulator of the alternative complement pathway. The complement cascade is a critical arm of the innate immune system responsible for clearing cellular debris, recognizing foreign pathogens, and mediating inflammatory processes. Without adequate regulation by factor H and related proteins (CFHR family), uncontrolled complement activation can attack host cells. In the eye, chronic, low-grade complement dysregulation in the retinal pigment epithelium and Bruch's membrane can promote inflammatory tissue damage and the accumulation of extracellular deposits known as drusen.
Research Findings and Evidence Strength
Scientific evaluation of rs3916970 indicates limited direct evidence as a causal driver of disease. Instead, genome-wide association studies (GWAS) and fine-mapping efforts treat it primarily as a marker that tags broader complement-associated haplotypes. Historically, well-known coding variants like Y402H (rs1061170) and adjacent structural variations (such as CFHR3-CFHR1 deletions) have accounted for the majority of the strong statistical association with age-related macular degeneration. Polymorphisms like rs3916970 correlate with modest shifts in complement regulation, but their individual effect sizes remain modest and are primarily defined through their co-inheritance with wider regulatory blocks.
Population Distribution and Ancestral Patterns
The frequency of rs3916970 varies across worldwide populations. In European and related ancestral groups, the minor allele maintains a frequency of approximately 0.30 (30%), indicating that both heterozygous and homozygous variant genotypes are commonly encountered in these cohorts. In other populations, including East Asian and African ancestries, the structure of linkage disequilibrium across the CFH locus differs significantly. Consequently, the correlation between this marker and specific functional changes in complement activation cannot be uniformly extrapolated from one ancestral background to another.
Translating Findings to Daily Health
Carrying an altered genotype at rs3916970 is not a clinical diagnosis and does not guarantee that an individual will develop vision loss or age-related macular degeneration. AMD is a multifactorial condition driven by complex interactions between multiple genetic variants, age, cardiovascular health, diet, and lifestyle exposures such as cigarette smoking. Genetic markers like rs3916970 provide research-grade statistical insights rather than definitive prognostic answers. Routine, comprehensive dilated eye examinations by an optometrist or ophthalmologist remain the established standard for evaluating retinal health.
How common is this variant?
The minor allele at rs3916970 displays a frequency of approximately 0.30 in European and related ancestral groups, meaning around half the population carries at least one copy. Frequencies and underlying linkage blocks vary substantially in other ancestral cohorts.
Frequently asked questions
Does having a variant at rs3916970 mean I will get macular degeneration?
No. Age-related macular degeneration is a multifactorial condition influenced by many genes, age, and environmental factors like smoking and nutrition. Having this non-coding variant merely marks a particular genetic haplotype; it is not a direct or inevitable cause of disease.
Is rs3916970 the same as the famous CFH Y402H mutation?
No, they are distinct genetic variants located in different parts of the CFH gene. The Y402H polymorphism (rs1061170) is a well-studied protein-altering missense variant, whereas rs3916970 is a non-coding variant that primarily serves as a genetic tag in haplotype analyses.
Can diet or supplements counteract the effects of CFH variants?
A diet rich in dark leafy greens, omega-3 fatty acids, and antioxidants generally supports overall retinal health. While specialized nutritional formulas exist for individuals diagnosed with specific stages of macular degeneration, you should consult an eye-care specialist before beginning targeted supplementation.
Should I speak to a doctor about my rs3916970 genotype?
There is no standard medical protocol or specific treatment triggered solely by rs3916970 results. However, if you have a family history of retinal disorders or vision changes, discussing your general risk profile with an ophthalmologist or optometrist during regular dilated eye exams is always recommended.
Sources & further reading
Educational information only, last refreshed 9/10/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs3916970?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CFH
This variant in the complement factor H gene is associated with altered regulation of the alternative complement pathway and increased susceptibility to age-related macular degeneration.
This regulatory variant in the CFH locus is linked to complement system dysregulation and is a recognized genetic risk factor for age-related macular degeneration.
Intronic single nucleotide variant in the CFH region associated with susceptibility to age-related macular degeneration (AMD).
Common variant in the CFH locus strongly associated with risk of age-related macular degeneration (AMD).
Genomic marker in CFH frequently co-inherited in haplotypes modulating risk of late-stage visual loss from macular degeneration.
Intronic marker in CFH forming critical susceptibility haplotypes for choroidal neovascularization and macular atrophy.